Ventyx Biosciences, Inc. (VTYX)

$4.38

-0.38

(-7.98%)

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Ventyx Biosciences, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 44.3% return, outperforming this stock by 130.2%

Performance

  • $4.37
    $4.76
    $4.38
    downward going graph

    0.23%

    Downside

    Day's Volatility :8.1%

    Upside

    7.89%

    downward going graph
  • $1.87
    $40.58
    $4.38
    downward going graph

    57.31%

    Downside

    52 Weeks Volatility :95.39%

    Upside

    89.21%

    downward going graph

Returns

PeriodVentyx Biosciences, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
127.75%
-0.5%
0.0%
6 Months
-72.78%
5.9%
0.0%
1 Year
-85.88%
3.1%
-1.9%
3 Years
-77.35%
14.2%
-21.8%

Highlights

Market Capitalization
329.2M
Book Value
$4.12
Earnings Per Share (EPS)
-3.3
Wall Street Target Price
10.8
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-40.06%
Return On Equity TTM
-64.56%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-207.8M
Diluted Eps TTM
-3.3
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.67
EPS Estimate Next Year
-2.59
EPS Estimate Current Quarter
-0.9
EPS Estimate Next Quarter
-0.87

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Ventyx Biosciences, Inc.(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
17
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 146.58%

Current $4.38
Target $10.80

Technicals Summary

Sell

Neutral

Buy

Ventyx Biosciences, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc.
-40.35%
-72.78%
-85.88%
-77.35%
-77.35%
Moderna, Inc.
Moderna, Inc.
-0.45%
20.22%
-27.91%
-35.9%
341.66%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.85%
6.85%
9.08%
78.94%
160.71%
Novo Nordisk A/s
Novo Nordisk A/s
-7.1%
22.03%
44.33%
239.61%
408.97%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.18%
5.53%
20.27%
79.84%
136.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc.
NA
NA
NA
-2.67
-0.65
-0.4
NA
4.12
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.21
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.84
25.84
1.46
45.15
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.4
3.36
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.57
28.57
0.53
16.72
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc.
Buy
$329.2M
-77.35%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.3B
341.66%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.6B
160.71%
25.84
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$559.8B
408.97%
46.75
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.7B
136.07%
28.57
36.68%

Institutional Holdings

  • BlackRock Inc

    6.44%
  • Vanguard Group Inc

    6.32%
  • Citadel Advisors Llc

    4.96%
  • Goldman Sachs Group Inc

    4.60%
  • Capital Research & Mgmt Co - Division 3

    3.97%
  • Logos Global Management LP

    3.38%

Corporate Announcements

  • Ventyx Biosciences, Inc. Earnings

    Ventyx Biosciences, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

we are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. ventyx now includes combined assets from three separate companies: oppilan pharma, targeting s1p1r, zomagen biosciences, targeting nlrp3 and the inflammasome, and ventyx biosciences, targeting tyk2.

Organization
Ventyx Biosciences, Inc.
Employees
79
CEO
Dr. Sheila K. Gujrathi M.D.
Industry
Services

FAQs